Chief Executive Officer
Dr. Velleca joined G1 as chief executive officer in 2014. Previously, he was at CGI Pharmaceuticals, where he guided the company from its inception through its establishment as a drug discovery company that brought multiple drug candidates into clinical trials. After CGI was acquired by Gilead Sciences, Dr. Velleca served as a senior advisor to Gilead in R&D Strategy and Corporate Development. Earlier in his career, Dr. Velleca was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine.
Dr. Velleca earned a BS from Yale University and an MD and PhD from Washington University in St. Louis. He has served on the board of directors and scientific advisory boards of several biotechnology companies, including Intellikine, an oncology therapeutics company that was acquired by Takeda in 2011. He most recently served as executive vice president at The Leukemia & Lymphoma Society.
Chief Medical Officer and Senior Vice President, R&D
Dr. Malik joined G1 as chief medical officer in 2014. Most recently, he served as chief medical officer and management board member at Agennix AG, where he was responsible for research and development. Prior to Agennix AG, he served as chief medical officer at Adherex Technologies, where he directed the company's global regulatory strategy and clinical development programs. Dr. Malik also served in oncology clinical development positions at EMD Pharmaceuticals and Bristol-Myers Squibb.
Dr. Malik received his MD from the University of Sheffield Medical School in the UK. He completed his residency at Duke University Medical Center and fellowships at Children's Hospital of Philadelphia and Duke University Medical Center. During his academic career, he was an assistant professor at the University of Virginia, where he conducted basic science and clinical research in addition to patient care and teaching.
Senior Vice President, Development Operations
Mr. Murdock joined G1 as Senior Vice President of Development Operations in 2017. Most recently he served as Vice President and Global Head of the Oncology Center of Excellence at QuintilesIMS, where he focused on developing insights and innovations that helped improve the probability of success for QuintilesIMS’ oncology customer development projects and programs.
Mr. Murdock has over 20 years of work experience as a successful senior executive in the medical research industry, specializing in oncology, multiple sclerosis and other autoimmune diseases. He is experienced at establishing operational excellence within culturally diverse environments with a successful track record of executing operational, clinical development, and commercial plans. Prior to QuintilesIMS, Mr. Murdock also held senior positions at Ergomed, Genzyme/Sanofi, ILEX Oncology, and US Oncology.
Mr. Murdock earned his M.S. in biology and a B.S. in microbiology from the University of Texas at Arlington.
Chief Financial Officer and Senior Vice President, Corporate Development
Mr. Phillips joined G1 as Chief Financial Officer and Senior Vice President of Corporate Development in 2017. Previously, he served as the Chief Financial Officer of two publicly traded biotech companies; Novavax, Inc. and Micromet, Inc., an oncology company acquired by Amgen in 2012. His early career includes 20 years of institutional public and private biotechnology investment experience.
Buck brings a long history of biotech specific finance and business experience to his responsibilities at G1 which include financial reporting, financial planning and analysis, financing strategy, investor relations, and corporate development activities, including strategic partnering and M&A.
Mr. Phillips received a Bachelor of Arts degree in economics from the University of Colorado at Boulder.
Vice President, Clinical Development and Product Team Leader – G1T38, G1T48
Dr. Andrew Beelen joined G1 Therapeutics in April 2016 as Senior Director of Clinical Development, serving as product team leader for G1T38. He has since taken on the additional responsibility of product team leader for G1T48 and was subsequently promoted to Vice President, Clinical Development. Prior to joining G1, Dr. Beelen served as Senior Oncology Medical Director at Quintiles.
Dr. Beelen has over 15 years of experience in pharmaceutical drug development, primarily in the oncology therapeutic area. Earlier in his career, he held increasing roles of responsibility including Vice President of Clinical Research at Myrexis and Director of Clinical Pharmacology and Discovery Medicine at GlaxoSmithKline, where he was responsible for the clinical pharmacology development program of lapatinib (TYKERB), including early phase combination chemotherapy studies.
Dr. Beelen earned his MD from SUNY Upstate Medical University in Syracuse, NY, and completed an internal medicine residency and clinical pharmacology fellowship at Dartmouth Hitchcock Medical Center in Lebanon, NH. During his clinical pharmacology fellowship, Dr. Beelen was a sub-investigator for several early phase oncology clinical trials.
Vice President, Global Regulatory Affairs
Ms. Lovejoy has nearly two decades of experience in global drug development, specializing in oncology. Most recently, she led global regulatory strategy as Senior Vice President, Global Regulatory Affairs and Head of Quality at Sierra Oncology. Earlier in her career, Ms. Lovejoy held roles of increasing responsibility at Endocyte, including Global Vice President of Regulatory Affairs, and at Genentech, where she served as regulatory lead on the AVASTIN® team. Ms. Lovejoy has led cross-functional team activities from IND applications, implementation and conduct of global clinical trials, successful negotiations with FDA and EMA regarding complex pivotal trials, to the submission and review of marketing applications.
Ms. Lovejoy has a Master of Science in Regulatory Affairs from San Diego State University, and a Bachelor of Science in Organizational Behavior from the University of San Francisco.
Vice President, Clinical Development and Product Team Leader – trilaciclib
Dr. Shannon Morris joined G1 Therapeutics in April 2017 as Vice President of Clinical Development, where she is responsible for the clinical development of trilaciclib. Prior to joining G1, Dr. Morris was Senior Director, Clinical Development, Immuno-oncology at MedImmune, a member of the Astra Zeneca Group. At MedImmune, she was instrumental in the approval of durvalumab in bladder cancer, the transition of the durvalumab/tremelimumab combination in hepatocellular carcinoma to late stage development, and the FTIH evaluation of the novel TLR 7/8 agonist MEDI9197. Prior to joining MedImmune, Dr. Morris rose to Senior Clinical Director at GlaxoSmithKline where she was the physician lead for the early phase development of the AKT and pan-PI3K inhibitor programs and participated in the FTIH dose escalation evaluation of the MEK inhibitor, trametinib which has subsequently been approved for use in BRAF-mutant metastatic melanoma.
Dr. Morris earned her MD and PhD from Case Western Reserve University in Cleveland, OH, and completed her medical residency and oncology fellowship at the University of North Carolina in Chapel Hill, NC. During her oncology fellowship, she participated in the Early Drug Development Fellowship in partnership with GlaxoSmithKline.
Vice President, Finance and Administration
Jennifer Moses began working with G1 Therapeutics in 2012 as a financial consultant and joined the company as VP of Finance and Administration in March 2015. Previously, Ms. Moses was a partner at the firm of RankinMckenzie, LLC a professional finance and accounting services firm, where she provided financial and accounting services to private, venture-backed companies. Prior to joining RankinMckenzie, Ms. Moses was a senior manager in the tax services group of Deloitte LLP, where she served clients ranging from small, emerging growth companies to large publicly traded corporations.
Ms. Moses received her BS in Accounting from Pennsylvania State University and is a certified public accountant.
Vice President, Technical Operations
Alexander (Lex) Smith began working with G1 Therapeutics in 2013 as a CMC consultant and joined the company as VP – Technical Operations in April 2015. Previously, Mr. Smith held VP positions at two biopharmaceutical companies, Serenex, and Viamet and also as VP, Development at a global consulting company, Fulcrum Pharma Developments. Additional pharmaceutical experience includes large, medium and small pharma companies including Burroughs-Wellcome, Glaxo-Wellcome, UCB Pharma and Triangle Pharmaceuticals. Mr. Smith’s experience encompasses all aspects of Chemistry, Manufacturing and Controls, drug substance, drug product and CMC regulatory affairs. NDAs where Mr. Smith provided a significant contribution include Zyban® SR Tablets, Valtrex® Tablets, and Emtriva® Capsules and Oral Solution.
Mr. Smith's education includes a BS in Chemistry from UNC-Chapel Hill and an MS in Pharmaceutical Chemistry from Lehigh University.
Chief Scientific Officer
Dr. Strum joined G1 as its first employee and founding chief scientific officer. He was instrumental in building the kinase drug discovery platform at G1 and recruiting, leading and managing the R&D team. Prior to G1, Dr. Strum was at GlaxoSmithKline (GSK) where he led drug discovery programs in cancer and metabolic diseases that brought multiple drug candidates into clinical development. He also played a key role in establishing and driving genomics research at GSK through the creation and management of an international gene expression department that included a human tissue repository and a human adipose-derived stem cell laboratory.
Dr. Strum obtained his PhD in biochemistry from Wake Forest University and did postdoctoral work with Dr. Bob Bell in molecular cancer biology at Duke University. His broad multidisciplinary experience in research and development includes being an author on more than 40 scientific papers, three book chapters and an inventor/co-inventor on 18 patents.